Gene Therapy Firm AMT Forced To Go Private, Backed By Forbion
This article was originally published in The Pink Sheet Daily
Amsterdam Molecular Therapeutics plans to be acquired by a newly formed private company, uniQure, and to delist from Euronext.
You may also be interested in...
With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.
Recent scientific advances and some initial biotech successes have spurred investors to look again at gene therapy, a space once given up for dead. Gene therapies seem particularly apt for ocular diseases, but the pathway to approval remains largely uncharted for young companies such as the four we profile in this issue: Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences.
UniQure made history in 2012 for winning approval in the EU for the first gene therapy accepted by regulators in a major market. CEO Jörn Aldag shares his views on uniQure's ambitious expansion plans.